First‑Line Oral Antibiotic Options for Uncomplicated Urinary Tract Infection in Women

Nitrofurantoin (Preferred Agent)

In adult women with uncomplicated lower urinary‑tract infection, nitrofurantoin 100 mg orally twice daily for 5 days achieves about 93 % clinical cure and 88 % microbiologic eradication, with worldwide resistance rates < 1 %【1】.
Nitrofurantoin preserves intestinal microbiota better than fluoroquinolones and broad‑spectrum cephalosporins, thereby lowering the risk of Clostridioides difficile infection and other collateral antimicrobial damage【1】.
Contraindicated when estimated glomerular filtration rate is < 30 mL/min/1.73 m² because therapeutic urinary concentrations cannot be reached【1】.

A single oral dose of fosfomycin trometamol 3 g provides roughly 91 % clinical cure and maintains therapeutic urinary concentrations for 24–48 hours in uncomplicated infections【1】.
Initial‑infection resistance rates are low (≈ 2.6 %), making fosfomycin a suitable alternative when nitrofurantoin is contraindicated or a single‑dose regimen is preferred【1】.
Fosfomycin should not be used for suspected pyelonephritis or other upper‑tract infections because tissue penetration is insufficient【1】.

When the uropathogen is susceptible, TMP‑SMX 160/800 mg orally twice daily for 3 days yields about 93 % clinical cure and 94 % microbiologic eradication【1】.
Prescribe TMP‑SMX only if both of the following are met: (1) local E. coli resistance < 20 %; and (2) the patient has not received TMP‑SMX in the preceding 3 months【2】.
If local resistance data are unavailable, default to nitrofurantoin or fosfomycin rather than risk TMP‑SMX failure【1】.

Routine urine culture is not required for otherwise healthy women with typical lower‑tract symptoms (dysuria, frequency, urgency) and no vaginal discharge【3】.
Obtain urine culture and susceptibility testing when any of the following occur: persistent symptoms after therapy, recurrence within 2–4 weeks, fever > 38 °C or flank pain suggestive of pyelonephritis, atypical presentation or vaginal discharge, or a history of recurrent infections or prior resistant isolates【1】.

Beta‑lactam agents (amoxicillin‑clavulanate, cefdinir, cefpodoxime, ceftibuten) for 3–7 days achieve only ~ 89 % clinical cure and ~ 82 % microbiologic eradication, which is inferior to nitrofurantoin, fosfomycin, or TMP‑SMX【1】.
Amoxicillin or ampicillin alone should be avoided because worldwide E. coli resistance exceeds 55–67 %【1】.
Fluoroquinolones (e.g., levofloxacin 250 mg once daily for 3 days) are reserved for culture‑proven resistant pathogens or documented failure of first‑line therapy; global resistance exceeds 10 % and serious adverse effects outweigh benefits in uncomplicated UTI【1】.

If symptoms persist after 2–3 days or recur within 2 weeks, obtain a urine culture and susceptibility test immediately, then switch to a different antibiotic class for a full 7‑day course【2】.
Persistent fever beyond 72 hours despite appropriate therapy warrants renal imaging (ultrasound or CT) to exclude obstruction, calculi, or abscess formation【1】.

Do not treat asymptomatic bacteriuria in non‑pregnant, non‑catheterized women, as it provides no clinical benefit and promotes resistance【3】.
Do not prescribe TMP‑SMX without confirming that local E. coli resistance is < 20 %; failure rates rise sharply above this threshold【1】.
Do not use nitrofurantoin for suspected pyelonephritis or when eGFR < 30 mL/min/1.73 m²【1】.
Do not use oral fosfomycin for upper‑tract involvement; instead select parenteral therapy such as ceftriaxone or a documented‑susceptible fluoroquinolone【1】.

Confirm uncomplicated UTI (no fever, flank pain, pregnancy, catheter, immunosuppression, or recent instrumentation)【3】.
If eGFR ≥ 30 mL/min/1.73 m² → prescribe nitrofurantoin 100 mg PO BID for 5 days【1】.
If nitrofurantoin is contraindicated → prescribe fosfomycin 3 g single oral dose【1】.
If both nitrofurantoin and fosfomycin are unsuitable and local E. coli TMP‑SMX resistance < 20 % and no recent TMP‑SMX use → prescribe TMP‑SMX 160/800 mg PO BID for 3 days【1】.
If all first‑line agents are contraindicated → consider a beta‑lactam agent (amoxicillin‑clavulanate, cefdinir, cefpodoxime) for 3–7 days, recognizing its inferior efficacy【1】.